Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

11.19 +0.75 (+7.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Iovance Biotherapeutics Inc

< Previous 1 2 3 Next >
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Iovance also to Participate in Upcoming November Conferences 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI. 
Via MarketBeat
Topics Cannabis
Exposures Cannabis
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Near Top of Volume Charts in Wednesday Trading
Via Investor Brand Network
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.